These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
571 related articles for article (PubMed ID: 26172401)
21. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725 [TBL] [Abstract][Full Text] [Related]
22. Discovery and characterization of novel mutant FLT3 kinase inhibitors. Weisberg E; Choi HG; Barrett R; Zhou W; Zhang J; Ray A; Nelson EA; Jiang J; Moreno D; Stone R; Galinsky I; Fox E; Adamia S; Kung AL; Gray NS; Griffin JD Mol Cancer Ther; 2010 Sep; 9(9):2468-77. PubMed ID: 20807780 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition. Zhu R; Shirley CM; Chu SH; Li L; Nguyen BH; Seo J; Wu M; Seale T; Duffield AS; Staudt LM; Levis M; Hu Y; Small D Leukemia; 2024 Jul; 38(7):1581-1591. PubMed ID: 38811818 [TBL] [Abstract][Full Text] [Related]
24. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors. Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377 [TBL] [Abstract][Full Text] [Related]
25. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472 [TBL] [Abstract][Full Text] [Related]
26. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Yang X; Sexauer A; Levis M Br J Haematol; 2014 Jan; 164(1):61-72. PubMed ID: 24116827 [TBL] [Abstract][Full Text] [Related]
27. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation. Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603 [No Abstract] [Full Text] [Related]
28. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638 [TBL] [Abstract][Full Text] [Related]
30. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830 [TBL] [Abstract][Full Text] [Related]
31. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205 [TBL] [Abstract][Full Text] [Related]
32. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia. Hu C; Zhang Y; Yang J; Xu Y; Deng T; Li Y; Xu S; Wang S; Wang P Cell Commun Signal; 2024 Jul; 22(1):355. PubMed ID: 38978049 [TBL] [Abstract][Full Text] [Related]
33. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109 [TBL] [Abstract][Full Text] [Related]
34. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382 [TBL] [Abstract][Full Text] [Related]
35. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells. Darici S; Jørgensen HG; Huang X; Serafin V; Antolini L; Barozzi P; Luppi M; Forghieri F; Marmiroli S; Zavatti M Adv Biol Regul; 2023 Aug; 89():100974. PubMed ID: 37245251 [TBL] [Abstract][Full Text] [Related]